Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Medicus Pharma Ltd (MDCX)

Medicus Pharma Ltd (MDCX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 45,159
  • Shares Outstanding, K 22,029
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,160 K
  • EBIT $ -29 M
  • EBITDA $ -29 M
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.37
  • Number of Estimates 2
  • High Estimate -0.32
  • Low Estimate -0.42
  • Prior Year -0.18
  • Growth Rate Est. (year over year) -105.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.67 +22.39%
on 12/03/25
2.55 -19.61%
on 11/17/25
-0.25 (-10.87%)
since 11/05/25
3-Month
1.67 +22.39%
on 12/03/25
3.05 -32.79%
on 09/23/25
+0.17 (+9.04%)
since 09/05/25
52-Week
1.67 +22.39%
on 12/03/25
8.94 -77.07%
on 05/20/25
-0.85 (-29.31%)
since 12/05/24

Most Recent Stories

More News
Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction

MDCX : 2.05 (+6.77%)
Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President

PHILADELPHIA, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development...

MDCX : 2.05 (+6.77%)
Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President

Carolyn Bonner Succeeds James ('Jim') Quinlan Who Has Resigned for Health Reasons After Taking Medical Leave in September 2025

MDCX : 2.05 (+6.77%)
Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

PHILADELPHIA, Nov. 24, 2025 (GLOBE NEWSWIRE) -- November is Men’s Health Awareness Month, a time to spotlight the latest medical breakthroughs that may transform how we detect and treat cancer– especially...

MDCX : 2.05 (+6.77%)
Medicus Pharma Ltd. Announces Filing of FDA Commissioner’s National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

PHILADELPHIA, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs...

MDCX : 2.05 (+6.77%)
Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

SKNJCT-003 Doxorubicin containing Microneedle Array (D-MNA) clinical development program to non-invasively treat BCC aligns with national priorities of public health impact, unmet medical need, access,...

MDCX : 2.05 (+6.77%)
Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

Clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next generation GnRH antagonist, are steadily advancing

MDCX : 2.05 (+6.77%)
Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

THE SKNJCT-003 CLINICAL STUDY EXPANSION INTO THE UNITED KINGDOM TO FURTHER ENABLE GLOBAL PATIENT RECRUITMENT AND CLINICAL DATASET TOWARD A PIVOTAL STUDY PROGRAM

MDCX : 2.05 (+6.77%)
BTV Spotlights: Netcoins, Kodiak, Sitka, Kneat, Highland Copper, Northstar Clean Technologies, Mineros, Stillwater, Medicus, & Newcore

Watch on FOX Business NewsSaturday, Nov 8 at 5:00 PM EST and via the links belowVancouver, British Columbia--(Newsfile Corp. - November 10, 2025) - Tune into BTV-Business Television and Discover Investment...

ROOOF : 0.2048 (+0.69%)
KSI.TO : 4.70 (-0.42%)
MDCX : 2.05 (+6.77%)
KDK.VN : 0.700 (+1.45%)
BIGG.VN : 0.080 (-5.88%)
NCAU.VN : 0.670 (+3.08%)
SITKF : 0.7050 (-0.48%)
BBKCF : 0.0622 (-1.27%)
PGEZF : 0.3080 (-1.28%)
SIG.VN : 0.960 (-4.95%)
PGE.VN : 0.425 (-4.49%)
KDKCF : 0.5013 (+1.19%)
Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECTâ„¢ in Patients with Gorlin Syndrome

PHILADELPHIA, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs...

MDCX : 2.05 (+6.77%)

Business Summary

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

See More

Key Turning Points

3rd Resistance Point 2.29
2nd Resistance Point 2.20
1st Resistance Point 2.12
Last Price 2.05
1st Support Level 1.95
2nd Support Level 1.86
3rd Support Level 1.78

See More

52-Week High 8.94
Fibonacci 61.8% 6.16
Fibonacci 50% 5.31
Fibonacci 38.2% 4.45
Last Price 2.05
52-Week Low 1.67

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar